阿加特罗班相关的不良事件:基于FDA不良事件报告系统 (FAERS) 的分析
Changyu Ren1,2, Guimu Guo1, YiXuan Wang2,3
1Department of Pharmacy, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, #18 Daoshan Road, Fuzhou, 350001, China.
Cardiovascular toxicology
|October 17, 2025
概括
这项研究使用FAERS数据分析了阿罗班的不良事件 (AE),识别了已知的风险和新的安全信号,如血管伪动脉瘤. 这些发现旨在提高临床医生的意识和患者安全.
科学领域:
- 药物监督 药物监督 药物监督
- 药物安全分析 药物安全分析
- 现实世界的证据.
背景情况:
- 阿尔加特罗班是一种抗凝剂,已知存在安全问题.
- 现实世界的不良事件 (AE) 数据对于理解药物安全性概况至关重要.
- FAERS数据库提供了大量药监测研究的存储库.
研究的目的:
- 从FAERS数据库中挖掘和分析与 argatroban相关的不良事件 (AE).
- 为了确定已知和潜在的新安全信号的 argatroban.
- 提高医疗保健专业人员对阿格拉斯罗班相关风险的认识.
主要方法:
- 利用了FAERS从2004年第一季度到2024年第三季度的数据.
- 采用的信号挖掘方法:报告概率比率 (ROR),比例报告比率 (PRR),贝叶斯信任传播神经网络 (BCPNN) 和多项马鱼缩小器 (MGPS).
- 在54,336,884份AE报告中分析了2,233份与arithroban相关的AE报告.
主要成果:
- 在与 argatroban.com相关的25个系统器官类中确定了110个首选术语.
- 已确认的已知副作用:凝血时间延长,出血,肝功能异常.
- 检测到潜在的新AE信号:血管类伪动脉瘤,逆皮质血瘤,,血栓性血性紫外线,急性心力衰竭,心房隔膜缺陷,狂宫溶解.
- 大多数AE发生在成年人 (≥65岁),轻微男性占主导地位.
- 事件发生的中位时间为2.00天;大多数AE发生在30天内.
结论:
- 法尔斯数据库分析显示了阿格罗班相关的副作用,包括新的潜在风险.
- 这些发现强调了需要提高人们对 argatroban 的安全概况的认识.
- 这项研究支持及时干预,以提高患者安全和管理与药物相关的风险.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Therapeutic Drug Monitoring: Affecting Factors
200
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
200
Venous Thrombosis III: Interprofessional Care
278
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
278


